Baxalta Inc (BXLT)
Baxalta develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions. Co. is also investing in new disease areas, including oncology, as well as emerging technology platforms, including gene therapy and biosimilars. Co.'s business consists of a portfolio of products serving patient needs in a variety of ways. Co.'s four groups consist of Hemophilia, Inhibitor Therapies, Immunoglobulin Therapies and BioTherapeutics.
|
April 19, 2024 12:47 PM Eastern
Buy (3.00 out of 4)
100th percentile
|
|